SCHEMBL4889947

SCHEMBL4889947

O=C(NN=C(C=NO)c1ccc(Oc2ccccc2)cc1)c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
ALDH1A1 P00352 3/20 0.49
GRM5 P41594 2/20 0.44
HTT P42858 3/20 0.44
RAB9A P51151 2/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
KDM1A O60341 1/20 0.44
PYGL P06737 1/20 0.43
PYGM P11217 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CASP3 P42574 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
SERPINE1 P05121 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889942 1.00 MAPT (0.49) MAPTALDH1A1GRM5HTTRAB9A
SCHEMBL4890021 0.91 MAPT (0.57) MAPTALDH1A1HTTRAB9ALMNA
SCHEMBL4890013 0.91 MAPT (0.57) MAPTALDH1A1HTTRAB9ALMNA
SCHEMBL4886315 0.87 MAPT (0.58) MAPTALDH1A1GRM5HTTRAB9A
SCHEMBL4886333 0.87 MAPT (0.58) MAPTALDH1A1GRM5HTTRAB9A
SCHEMBL4878943 0.86 MAPT (0.54) MAPTALDH1A1HTTRAB9ALMNA
SCHEMBL4878940 0.86 MAPT (0.54) MAPTALDH1A1HTTRAB9ALMNA
SCHEMBL2907122 0.86 MAPT (0.53) MAPTALDH1A1HTTRAB9ALMNA
SCHEMBL2907123 0.86 MAPT (0.53) MAPTALDH1A1HTTRAB9ALMNA
SCHEMBL4877413 0.82 MCL1 (0.50) MAPTALDH1A1RAB9ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed
EP-1725227-A1 USE OF NEW LIPOXYGENASE INHIBITORS Biolipox AB (SE) 2006-11-29 EP disclosed
WO-2005084656-A1 USE OF NEW LIPOXYGENASE INHIBITORS BIOLIPOX AB (SE) 2005-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 MAPT 4603/4885ALDH1A1 464/4885GRM5 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.